Artiva Biotherapeutics, Inc. (ARTV) Investor Relations Documents
Artiva Biotherapeutics, Inc. (ARTV) investor relations documents from the company's IR site: 7 presentations, 12 press releases; latest deck 2026-06-08. Read in-app with summaries. First-party data.
Presentation Open Event Link, PDF file, June 8, 2026, (opens in new window): Artiva Biotherapeutics reports positive clinical data for AlloNK in autoimmune diseases, targeting a $5B market for refractory rheumatoid arthritis patients.
Investor relations documents — source: company IR site| Published | Type | Document |
|---|
| 2026-08-06 | Press release | Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights |
| 2026-07-17 | Press release | Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-23 | Press release | Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference |
| 2026-06-23 | Press release | Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference |
| 2026-06-08 | Press release | Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Ar |
| 2026-06-08 | Presentation | Presentation Open Event Link, PDF file, June 8, 2026, (opens in new window) |
| 2026-06-08 | Press release | Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Ar |
| 2026-06-06 | Presentation | Presentation Open Event Link, PDF file, June 6, 2026, (opens in new window) |
| 2026-06-05 | Presentation | Presentation Open Event Link, PDF file, June 5, 2026, (opens in new window) |
| 2026-06-01 | Presentation | Download (opens in new window) |
| 2026-05-28 | Presentation | Presentation Open Event Link, PDF file, June 6, 2026, (opens in new window) |
| 2026-05-28 | Presentation | Presentation Open Event Link, PDF file, June 6, 2026, (opens in new window) |
| 2026-05-28 | Press release | Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference |
| 2026-05-19 | Press release | Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head |
| 2026-05-19 | Press release | Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Ora |
| 2026-05-08 | Press release | Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants |
| 2026-05-08 | Press release | Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to In |
| 2026-04-08 | Press release | Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference |
| 2026-01-27 | Presentation | Presentation Open Event Link, PDF file, February 5, 2026, (opens in new window) |
ARTV overview · ARTV earnings · ARTV financials · ARTV KPIs · ARTV ownership · ARTV peers · ARTV filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.